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Abstract
Introduction: The ACTH receptor (ACTHR) is primarily expressed in the adrenal cortex. Previous studies focused on the regulatory function 
of ACTHR in glucocorticoid secretion, but research on adrenal tumours is rare. The aim of this study was to evaluate ACTHR expression 
in common adrenal adenomas and investigate its influence on adrenal tumorigenesis using adrenocortical H295R cells.
Materials and methods: Real-time polymerase chain reaction and western blot were used to detect the expression of ACTHR in 18 
aldosterone-producing adenomas, 16 cortisol-producing adenomas, 9 non-functional adenomas, and 12 normal adrenal samples. Lentiviral 
vector pLVX-mCMV-ACTHR-ZsGreen was transfected into the H295R cells to increase ACTHR expression. WST-1 and cell count were 
applied to evaluate cell proliferation at different ACTHR levels. TUNEL staining was used to measure cell apoptosis. 
Results: Compared with normal adrenal samples, the aldosterone-producing adenoma samples had higher ACTHR mRNA and protein 
levels. However, the mRNA and protein levels of ACTHR in non-functional adenomas and cortisol-producing adenomas were lower than 
those in the normal adrenal samples. Proliferative activity in the experimental cells was higher than that in the control cells in the first three 
days. The proliferative activity peaked in the second day. However, this trend was reversed in the fourth day and became more apparent 
with time. By contrast, TUNEL staining showed that ACTHR overexpression did not induce a significant difference between the two groups. 
Conclusions: Differential ACTHR expression may be determined by different types of adrenocortical tumours. ACTHR is more likely to 
have induced the proliferation rather than the apoptosis of H295R cells. (Endokrynol Pol 2017; 68 (5): 512–518)
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Streszczenie
Wstęp: Receptor kortykotropiny (adrenocorticotropic hormone receptor, ACTHR) występuje głównie w korze nadnerczy. Prowadzono wcze-
śniej badania dotyczące regulacyjnej funkcji ACTHR w wydzielaniu glikokortykoidów, lecz rzadko obejmowały one chorych z guzami 
nadnerczy. Badanie przeprowadzono w celu oceny ekspresji ACTHR w najczęstszych gruczolakach nadnerczy i zbadania jej wpływu na 
rozwój tych nowotworów w komórkach kory nadnerczy ludzkich linii H295R.
Materiał i metody: Do wykrycia ekspresji ACTHR w 18 gruczolakach wydzielających aldosteron, 16 gruczolakach wydzielających kor-
tyzol, 9 gruczolakach nieczynnych hormonalnie i 12 próbkach prawidłowych nadnerczy użyto reakcji łańcuchowej polimerazy w czasie 
rzeczywistym oraz metody Western blot. W celu zwiększenia ekspresji ACTHR transfekowano wektor lentiwirusowy pLVX-mCMV-AC-
THR-ZsGreen do komórek H295R. Proliferację komórek przy różnych poziomach ekspresji ACTHR oceniono na podstawie WST-1 oraz 
liczby komórek. W celu zmierzenia apoptozy komórek zastosowano barwienie metodą TUNEL. 
Wyniki: W porównaniu z próbkami prawidłowych nadnerczy w próbkach gruczolaków wydzielających aldosteron stwierdzono wyższą 
ekspresję mRNA i białka ACTHR. Jednak ekspresja mRNA i białka ACTHR w gruczolakach nieczynnych hormonalnie oraz w gruczola-
kach wydzielających kortyzol była niższa niż w próbkach prawidłowych nadnerczy. W ciągu 3 pierwszych dni aktywność proliferacyjna 
w komórkach eksperymentalnych była wyższa niż w komórkach kontrolnych. Aktywność proliferacyjna osiągnęła maksymalną wartość 
w drugim dniu. Jednak w czwartym dniu ta tendencja uległa odwróceniu, co było wyraźniejsze w miarę upływu czasu. Z kolei barwienie 
metodą TUNEL wykazało, że nad ekspresja ACTHR nie spowodowała istotnej różnicy między grupami. 
Wnioski: Zróżnicowanie ekspresji ACTHR może wynikać z różnych typów guzów nadnerczy ocenianych w badaniu. Wydaje się, że 
ACTHR pobudza proliferację, a nie apoptozę komórek H295R. (Endokrynol Pol 2017; 68 (5): 512–518)
Słowa kluczowe: receptor kortykotropiny, guz nadnerczy, proliferacja, komórki H295R
Introduction
Adrenal diseases characterised by hormonal disor-
ders or neoplasms are caused by adrenal tumours or 
hyperplasia. Pathological findings indicate that most 
adrenal diseases are diagnosed with benign adenoma. 
By contrast, adrenocortical carcinoma is extremely 
rare. However, different diseases determine distinct 
treatments. Surgeons need to confront different preop-
erative preparations and surgical risks. Therefore, the 
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pathogenesis of adrenal tumours must be investigated 
to discover new treatments.
The adrenocorticotropic hormone receptor (ACTHR, 
also called MC2R) is a G-protein coupled, seven-trans-
membrane receptor that transmits the adrenocortico-
tropic hormone (ACTH) signal to induce related hor-
mone production in adrenocortical cells by the cAMP/ 
/PKA pathway [1]. This receptor is primarily expressed 
in the adrenal cortex [2]. Previous studies focused on 
the regulatory function of ACTHR in glucocorticoid 
secretion, but research on adrenal tumours is rare. 
Recent documents have shown that ACTH is crucial in 
adrenal cell growth and differentiation; ACTH is even 
considered as a proliferation inducer [3]. So far, a few 
studies have experimented at tissue level [2, 4]; how-
ever, studies at the cellular level are limited. Therefore, 
we explored the effects of ACTHR on adrenal tumour 
formation at the tissue and cellular levels using human 
NCI-H295R adrenocortical cells.
Materials and methods
Tissue collection
From July 2013 to August 2014, a total of 55 patients 
underwent retroperitoneoscopic adrenalectomy 
because of adrenal tumour (Table I). There were 29 
men and 26 women, aged 34 to 65 years (mean 47). Of 
these 55 patients (31 on the left side, 24 on the right 
side), 18 aldosterone-producing adenomas (APAs), 
16 cortisol-producing adenomas (CPAs), and nine 
non-functional adenomas (NFAs) were collected from 
patients with clinically and pathologically confirmed 
diseases. Twelve normal adrenal (NAs) samples were 
obtained from patients who underwent adrenalectomy 
along with nephrectomy because of renal carcinoma or 
renal pelvic carcinoma. All samples were collected by 
surgical resection. Immediately after surgery, samples 
were snap-frozen in liquid nitrogen and experiments 
were performed. ACTHR expression was determined 
by western blot and real-time polymerase chain reac-
tion (PCR). 
The study was approved by the Ethical Committee 
of Zhongnan Hospital of Wuhan University and car-
ried out in compliance with the Helsinki declaration. 
Participants signed an informed consent prior to enrol-
ment in the study.
Cell culture
H295R adrenocortical cells were obtained from the 
American Type Culture Collection (Rockville, MD). Cells 
were cultured in DMEM/F12 medium supplemented 
with 2.5% Nu Serum (BD Biosciences, Bedford, MA), 
and 1% ITS+1 (Sigma-Aldrich, St. Louis, MO). The cells 
were grown at 37°C in a humid atmosphere of 95% 
air/5% CO2. Transfection or treatment was initiated 24 
h after reseeding the cells (about 80～90% confluence). 
Lentiviral vector constructs and transfection
Lentiviral vector pLVX-mCMV-ACTHR-ZsGreen (Bio-
wit, Shenzhen, China) was used to increase ACTHR ex-
pression. The virus containing the expression vector but 
lacking the ACTHR cDNA was also transfected into the 
H295R cells to act as the negative control group. Normal 
H295R cells, without any virus, were used as a blank 
control. According to the manufacturer’s directions, 
cells were infected by virus (multiplicity of infection 
= 20) and 8 µg/mL polybrene was added. The infected 
cells were grown at 37°C in a humid atmosphere of 95% 
Table I. Perioperative data
Tabela I. Dane przedoperacyjne
APA CPA NFA NA
Number of patients
Age (y)
Gender (n)
Male
Female
BMI [kg/m2]
Laterality (n)
Left 
Right 
Operation time (min)
Tumor size [cm]
18
46.2 ± 6.5
10
8
25.4 ± 3.4
11
7
52.1 ± 10.3
1.9 ± 0.3
16
48.1 ± 7.1
7
9
25.8 ± 4.5
9
7
53.6 ± 13.1
2.1 ± 0.6
9
45.9 ± 8.3
5
4
24.9 ± 4.1
5
4
49.5 ± 14.8
2.8 ± 0.8
12
50.3 ± 7.7
7
5
23.8 ± 3.6
6
6
59.4 ± 15.2
—
APA: aldosterone-producing adenoma; CPA: cortisol-producing adenoma; NFA: non-functional adenoma; NA: normal adrenal
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air/5% CO2. Medium was changed 24 h later. Cells were 
harvested to perform subsequent assays according to 
different experiments 48 h later.
Real-time PCR
Total RNA was extracted using a Total RNA Miniprep Kit 
(Axygen, Union, CA) according to the manufacturer’s 
instructions. For cDNA synthesis, 1 µg of RNA was re-
verse transcribed using a First Strand cDNA Synthesis 
Kit (MBI Fermentas, Vilnius, Lithuania). To ACTHR 
primers, we refer to the previous publication [5]: 
forward, 5’-CCCAGAAAGTTCCTGCTT-3’, reverse, 
5’- ATATCTCCTCCGGCAAAA-3’; (GAPDH) forward, 
5′-GTGAAGGTCGGAGTCAACG-3′, reverse, 5’-TGAG-
GTCAATGAAGGGGTC-3′. Real-time PCR was carried 
out using the Rotor Gene 3000 sequence detection 
system (Qiagen, Venlo, Holland). A 25 µL total volume 
consisted of 2 µL of cDNA, 12.5 µL of SYBR Green qPCR 
Master Mix (2×; MBI Fermentas, Lithuania), and 0.3 µM 
forward and reverse primers. The cycling conditions 
were 95°C for 10 min, 40 cycles at 95°C for 15 s, and 60°C 
for 1 min. All samples were tested in triplicate under 
these conditions, and the mRNA levels of ACTHR were 
standardised against GAPDH.
Western blot
Each sample was lysed in RIPA buffer. Protein concen-
tration was measured using a standard BCA protein 
assay kit (Beyotime, Haimen, China). Each sample was 
electrophoresed on 12% SDS-PAGE gels and transferred 
onto polyvinylidene difluoride membranes (Millipore, 
Billerica, MA). The blots were probed with anti-ACTHR 
(2 µg/mL, polyclonal, Abcam, UK) and anti-β-actin 
(Santa Cruz, CA). Expression was detected using an 
Ultra enhanced chemiluminescence kit (BioInd, Israel). 
Proteins were quantified using the software Quantity 
One (Bio-Rad, Hercules, USA).
Figure 1. Lentiviral vector pLVX-ACTHR effectively increased 
ACTHR expression at protein level (A) and mRNA level (B). 
The protein and mRNA levels of ACTHR in the experiment cells 
increased by 1.4-fold (ratio of relative intensities: 0.54 ± 0.06 
and 0.39 ± 0.07) (P = 0.028) and 8-fold (P < 0.01), respectively, 
compared with those in the control cells
Rycina 1. Wektor lentiwirusowy pLVX-ACTHR skutecznie 
zwiększył ekspresję ACTHR, zarówno na poziomie białka (A), 
jak i mRNA (B). Ekspresja białka i mRNA ACTHR w komórkach 
eksperymentalnych zwiększyła się odpowiednio 1,4-krotnie 
(stosunek względnej intensywności: 0,54 ± 0,06 i 0,39 ± 0,07) 
(p = 0,028) i 8-krotnie (p < 0,01) w porównaniu z ich ekspresją 
w komórkach kontrolnych
ACTHR:34KD
Control pLVX-ACTHR
AC
TH
R 
m
RN
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lev
el
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β-actin:43KD
A
B
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Figure 2. The expression of ACTHR at protein (A) and mRNA 
levels (B) in adrenal tumors and normal adrenal. At the protein 
level, the relative intensities of theses four kinds of tissues were 0.28 
± 0.06; 0.31 ± 0.05; 0.81 ± 0.04 and 0.49 ± 0.04 (P = 0.017), 
respectively. At the gene level, NA mRNA level was considered as 
100 so as to facilitate comparison. It was 2.16 and 2.31 times higher 
than the CPA and NFA groups. The mRNA level of ACTHR was 
3.52-fold higher in APA than that in NA (P = 0.002)
Rycina 2. Ekspresja ACTHR na poziomie białka (A) i mRNA (B) 
w guzach nadnerczy i nadnerczach prawidłowych. Na poziomie 
białka względna intensywność w czterech ocenianych w badaniu 
typach tkanek wynosiła odpowiednio 0,28 ± 0,06; 0,31 ± 0,05; 
0,81 ± 0,04 i 0,49 ± 0,04 (p = 0,017). Na poziomie genu w celu 
ułatwienia porównań przyjęto ekspresję w prawidłowych 
nadnerczach (normal adrenal, NA) mRNA jako 100. Była ona 
2,16- i 2,31-krotnie wyższa niż w gruczolakach wydzielających 
kortyzol (cortisol-producing adenoma, CPA) i gruczolakach 
nieczynnych hormonalnie (non-functioning adenoma, NFA). 
Ekspresja mRNA ACTHR była 3,52-krotnie wyższa w gruczolakach 
wydzielających aldosteron (aldosterone-producing adenoma, 
APA) niż w prawidłowych nadnerczach (p = 0,002)
A
B
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Proliferation assays
To measure proliferation, 2 × 103 cells were seeded in 
96-well plates. After 24 h of transfection, the prolifera-
tion rates of the experimental and control cells were 
studied with the WST-1 proliferation assay (Beyotime, 
Haimen, China). Absorption values were detected every 
24 h in the next four days. Cell numbers were counted 
daily. Results are expressed as the average of at least 
three independent experiments performed in duplicate.
Cell apoptosis
Apoptosis was assayed using a One Step TUNEL Ap-
optosis Assay Kit (Beyotime, Haimen, China) according 
to the producer’s protocol. In brief, the cells were fixed 
with 4% paraformaldehyde after 48 h of transfection, 
permeabilised with 0.1% Triton X-100 in sodium cit-
rate, and incubated for 60 min at 37°C in a humidified 
atmosphere in the dark after adding the TUNEL reac-
tion mixture. Finally, the samples were analysed under 
a fluorescence microscope.
Statistical analysis
All experiments were repeated at least three times. 
Measurement data was analysed for statistical signifi-
cance using t tests and ANOVA (SPSS 15.0 software, 
Chicago, IL). Differences were considered significant 
at p < 0.05.
Results
ACTHR overexpression by lentiviral vector
When ACTHR expression vector was used to transfect 
H295R cells, real-time PCR and western blot showed 
that the protein and mRNA levels of ACTHR in the 
transfected cells increased by 1.4 and 8 fold (p < 0.01), 
respectively, compared with those in the control cells 
(Fig. 1). The ratio of relative intensities (Western blot) 
in the two groups was 0.54 ± 0.06 and 0.39 ± 0.07, 
respectively (p < 0.05). 
Expression of ACTHR in common adrenal tu-
mours
ACTHR expression in APA was higher than that in NA 
regardless of the protein or mRNA levels. The mRNA 
level of ACTHR was 3.52-fold higher in APA than that 
in NA (P < 0.05). Moreover, the protein levels in APA 
and NA were 0.81 ± 0.04 and 0.49 ± 0.04 (P < 0.05), 
respectively (Fig. 2). The mRNA and protein expres-
sion levels of ACTHR were decreased in CPA and NFA 
compared with those in NA. At the gene level, the 
former were 2.16 and 2.31 times higher than the latter, 
respectively (Fig. 2). At the protein level, these values 
were 0.49 ± 0.04 vs. 0.28 ± 0.06 and 0.49 ± 0.04 vs. 0.31 
± 0.05, respectively (p < 0.05).
ACTHR and cell proliferation in H295R cells 
H295R cells with high ACTHR expression level were 
cultured for five days, and cell numbers were counted 
daily. As shown in Figure 3, the absorption values 
(OD) increased as the number of days increased in the 
experimental and control cells. The proliferation of 
cells overexpressing ACTHR presented a double trend. 
Proliferative activity in the experimental group was 
higher than that in the control group in the first three 
days. This activity peaked on the second day. However, 
this trend was reversed on the fourth day and became 
more apparent with time. By contrast, this trend stead-
ily increased in the control cells (Fig. 3). Meanwhile, 
Figure 3A. Time-dependent proliferation in the ACTHR 
overexpression H295R cells and control cells. The absorption value 
of the experimental and control cells were detected in the next 4 d 
every 24 h, respectively; B. Effect of ACTHR on cell number after 
2 days (peak stage). The numbers of experimental and control cells 
peaked at 5.3 ± 0.21 x 103 and 3.8 ± 0.24 x 103 in the second day, 
respectively (P = 0.032)
Rycina 3A. Proliferacja komórek H295R z nadekspresją ACTHR 
i komórek kontrolnych w zależności od czasu. Wartość absorpcji 
w komórkach eksperymentalnych i kontrolnych mierzono 
w ciągu 4 następnych dni co 24 godziny; B. Wpływ ACTHR 
na liczbę komórek po 2 dniach (maksimum). Liczba komórek 
eksperymentalnych wzrosła w drugim dniu do maksymalnej 
wartości, wynoszącej odpowiednio 5,3 ± 0,21 x 103 i 3,8 ± 0,24 
x 103 (p = 0,032)
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the numbers of experimental and control cells peaked 
at 5.3 ± 0.21 × 103 and 3.8 ± 0.24 × 103 on the second 
day, respectively (p < 0.05). This result demonstrates 
the marked influence of high ACTHR expression on 
cell proliferation.
ACTHR and cell apoptosis
To study the effect of ACTHR on apoptosis, experimen-
tal and control cells were cultured for 48 h, and the 
percentage of apoptotic cells was measured by TUNEL 
staining. However, no significant differences were ob-
served between the two groups (p > 0.05).
Discussion
Unlike other tumours, adrenal neoplasm has many 
types and complex cell components. In addition, dis-
tinct zones secrete different hormones, and the cell 
characteristics and physiological functions differ. For 
example, Hornsby et al. reported that adrenal cell pro-
liferation and continuous remodelling usually occurs 
in the zona glomerulosa (ZG) and zona fasciculate (ZF), 
and cell death usually occurs in the zona reticularis [6]. 
In terms of ACTHR, most authors understand its effects 
indirectly by ACTH stimulation. Payet et al. injected 
ACTH into rats and found a 16-fold increase in the mi-
tosis rate in ZG, but ACTH had no effect on proliferation 
in the ZF, which developed marked hypertrophy [7]. 
Mazzuco et al. revealed that chronic stimulation by 
ACTH induces a phenotypic change in glomerulosa 
cells to fasciculata cells [8]. Thus, distinct cell features 
determine their differences in external stimulation.
In recent years, many authors explored the possible 
correlation of some genetic alteration with adrenal 
tumours, for example potassium channel (KCNJ5) in 
APA and protein kinase A catalytic subunit (PRKACA) 
in CPA. The majority of them focused on detecting 
somatic gene mutations in tissue specimens, such as 
KCNJ5 (p.G151R) and PRKACA (p.L206R). However, 
the overall prevalence of KCNJ5 or PRKACA mutations 
was just 40%, and the number of samples was not very 
large [9, 10]. The conclusions varied with gender, age, 
pathologic type, and different nationality. The genetic 
and cellular studies still need to be investigated more 
thoroughly.
We studied common adrenal tumours in a clinical 
setting and found that ACTHR expression increased in 
APA. Based on our previous study, we inferred that the 
possible pathogenic mechanisms may include the fol-
lowing factors and cell components. First, steroidogenic 
factor-1 (SF-1) is an important transcription factor that is 
required for adrenal cell proliferation and steroid hor-
mone secretion. As a target gene, the ACTHR promoter 
region has abundant SF-1 binding sites. After binding 
with these sites, SF-1 can promote ACTHR expression 
[11]. Our previous research confirmed that SF-1 in-
creases in APA [12]. Therefore, SF-1 overexpression in 
APA may promote ACTHR expression and aldosterone 
secretion. Second, although angiotensin II is the main 
regulator of aldosterone, ACTH also has an important 
function in this process. For APA patients, high ACTHR 
expression increases aldosterone production despite 
the normal plasma ACTH concentrations in these pa-
tients. Third, ACTHR is crucial in adrenal growth and 
maintenance. Otherwise, ACTHR mutation often causes 
adrenal atrophy [13]. Thus, the effect of ACTHR on cell 
growth may lead to tumorigenesis. Fourth, as the main 
cell component of APA, ZG has a potential tendency to 
proliferate and differentiate, and shows high expression 
of related biological indicators, including ACTHR [14].
By contrast, low ACTHR levels were present in 
CPA and NFA. The reasons for this result may be sum-
marised as follows. Cortisol, which is mainly produced 
from ZF, is regulated by ACTH, but has a negative 
feedback action to ACTH secretion. We inferred that 
the hypersecretion of glucocorticoid in CPA suppressed 
ACTH level and reduced ACTHR expression because 
ACTHR is positively regulated by ACTH [15]. In addi-
tion, other pathways (e.g. MRAP1 and AP-1) may be 
involved in the hypersecretion of glucocorticoid [16, 17]. 
To date, the expression of ACTHR in CPA was the 
most controversial issue. Different authors arrived 
at diverse conclusions from the 1990s until now [2, 
18, 19]. On the one hand, CPA has more complicated 
pathologic types and influence of internal environment 
than other adrenal tumours. Therefore, there may 
be selective differences in different publications. On 
the other hand, different experimental methods and 
fewer samples also lead to diverse conclusions. Unlike 
adrenal functional adenomas, NFA did not produce 
steroid hormone, and the main cell components of 
NFA were not determined. Thus, NFA probably has 
a different pathogenesis from functional adenomas. 
We could not exclude the possibility of tumour type 
differences or other distinct pathways involved in 
tumour formation, except ACTHR. Similar to adrenal 
carcinoma and adenoma, benign and malignant neo-
plasms have different pathogenic mechanisms even 
though they occur in the same organ. For example, 
many authors detected several indicators in adrenal 
benign and malignant tumours, but they found com-
pletely inconsistent expression levels of Ki-67, IGF-II, 
P450scc, etc. between the two tumour types [20, 21].
To further explore the effect of ACTHR, we per-
formed subsequent cellular research using H295R cells, 
which are commonly applied in experiments. The re-
sults of this study showed that high ACTHR expression 
initially increased and then decreased the proliferative 
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activity of H295R cells. Proliferative activity in the ex-
perimental group was higher than that in the control 
group in the first three days. This activity peaked on 
the second day. However, this trend was reversed on 
the fourth day and became more apparent with time. 
This result agreed with previous studies on the double 
effect of ACTH stimulation [22]. Many scholars proved 
that the effects of ACTH on adrenocortical hormones 
and cell growth were mainly reflected in the early stage 
(from 24 h to 72 h) after stimulation [23]. In this study, 
we found that this promoting function of ACTHR was 
time dependent. It may be determined by ACTH signal 
pathway characteristics and cell growth inhibitory influ-
ence during the later high-density growth environment. 
However, TUNEL apoptosis staining revealed no obvi-
ous difference between the two groups. Tumours are 
often caused by the imbalance between proliferation 
and apoptosis. Thus, ACTHR may be more likely to in-
duce the proliferation than the apoptosis of H295R cells.
Tumours are commonly caused by multiple factors/ 
/steps. In this study, we preliminary detected the ex-
pression and possible pathogenic influence of ACTHR 
in common adrenal tumours. Most adrenal tumours 
have endocrine functions, so the internal environment 
of an organism and interplay between the environment 
and organism must be investigated in further research. 
In-depth studies on ACTHR are expected to become 
a novel breakthrough in understanding adrenal tumo-
rigenesis and hormone secretion.
Conclusions
Adrenal diseases characterised by hormonal disorders 
or neoplasms are caused by adrenal tumours or hy-
perplasia. Tumours are often caused by the imbalance 
between proliferation and apoptosis. We detected the 
ACTHR levels in common adrenal tumours and inves-
tigated its influence on adrenal tumorigenesis using 
adrenocortical H295R cells. There were differential 
expressions of ACTHR in these tumours. Differential 
ACTHR expression may be determined by different 
types of adrenocortical tumours. ACTHR showed more 
obviously an effect on H295R cell proliferation than 
the apoptosis.
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